US20120148679A1 - Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition - Google Patents

Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition Download PDF

Info

Publication number
US20120148679A1
US20120148679A1 US13/377,869 US201013377869A US2012148679A1 US 20120148679 A1 US20120148679 A1 US 20120148679A1 US 201013377869 A US201013377869 A US 201013377869A US 2012148679 A1 US2012148679 A1 US 2012148679A1
Authority
US
United States
Prior art keywords
oil
composition
emulsion
carnosine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/377,869
Other languages
English (en)
Inventor
Janne Sande Mathisen
Henrik Mathisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smartfish AS
Original Assignee
Smartfish AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartfish AS filed Critical Smartfish AS
Assigned to SMARTFISH AS reassignment SMARTFISH AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATHISEN, HENRIK, MATHISEN, JANNE SANDE
Publication of US20120148679A1 publication Critical patent/US20120148679A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to food supplements.
  • the present invention relates to a composition comprising marine oil in a stable oil-in-water emulsion, further comprising at least one bioactive amino acid or peptide, or derivatives thereof
  • the present invention relates to a process for the production of said composition and the use of said composition as a functional or therapeutic composition.
  • omega-3 fatty acids The health promoting effects of omega-3 fatty acids are well known.
  • the health effects of various peptides and amino acids are partly known, but there is currently a strong scientific is interest in their many biological functions.
  • Proteins are structural or functional. Biologically active proteins include enzymes, immunoglobulins, hormones, neurotransmitters, transport proteins, receptors etc. A balanced diet revealing adequate levels of biologically active peptides and amino acids are important. Imbalances may lead to disorders of the endocrine, neurological, cardiovascular, immune system, digestive system and metabolism, and also structural imbalances in the cell membranes and muscular system.
  • the building blocks of human proteins are twenty amino acids that may be consumed from both plant and animal sources. Of these 20 amino acids, 9 are considered to be essential; i.e. cannot be synthesized within the body. The remaining “nonessential” amino acids can be synthesized endogenously, so also the highly functional bioactive peptides.
  • a typical western diet contains a lot of proteins.
  • the main sources of proteins in the diet are meat, chicken, milk and eggs. People with illnesses, who have been injured or are having severe stress, can benefit from a higher protein intake.
  • Another interesting aspect is that cooking methods and doneness of meat are related to CRC (colorectal cancer) risk, higher temperature leading to higher risk.
  • CRC colonal cancer
  • a 1991 Swedish case-control study showed that frequent consumption of fried meat with a heavily browned surface led to 3-fold increase in CRC risk. Since 1991, some twenty similar analytical studies have been published. Most studies confirm the Swedish findings: the intake of grilled, fried, barbecued and/or well-done red meat is more related to CRC risk than the intake of total red meat. This indicates that the health value of the meat and most likely the amino acids/peptides are reduced by harsh preparations.
  • Essential omega-3 fatty acids (DHA, EPA and DPA) have been investigated for a wide range of health conditions and diseases and found beneficial. These conditions are widely correlating with the ones found or indicated by various peptides.
  • omega-3 polyunsaturated fatty acids are so important to the development and is proper maintenance of the brain that some scientist even postulate that is was the ingestion of omega-3 that allowed the brain to evolve to the next stage in human development. While omega-3 was abundant in the human diet before the 20 th century, omega-3 is now seriously lacking.
  • n-3 fatty acids comprise approximately eight percent of the average human zo brain. Many scientists claim that DHA is structural and EPA is functional.
  • omega-3 fatty acids are instrumental in the function of brain cell membranes, which are important for the transmission of brain signals. By making cell membranes more fluid, omega-3 fatty acids, especially DHA, improve communication between the brain cells.
  • omega-3 can be incorporated into cell membranes and reduce the amount of arachidonic acid available for the synthesis of proinflammatory eicosanoids e.g. prostaglandins, leukotrienes.
  • omega-3 PUFA can also reduce the production of inflammatory cytokines.
  • Omega-3 fatty acids have been thoroughly examined for heart and cardiovascular health and found to be of great importance. Omega-3 has been shown beneficial for inflammation and oxidative stress conditions. Studies have also indicated positive effect on diabetes, osteophorosis, asthma, cancer etc.
  • the human body cannot synthesize omega-3 and the conversion from alfa-linolenic acid to long chain omega 3 is very limited—especially if there is a high intake of omega-6 from the diet. Intake of long chain omega-3 is needed from marine food sources, e.g. fish and seafood, or from supplements.
  • omega-6 content in the typical protein food sources is very high and has risen dramatically during the last decades. The reason to this is primarily that animal feed has had an enormous increase in omega-6 fatty acids. It provides cheaper and more stable feed. The feed has a high content of plant oils and seed, even recycled cooking oils, leading to high levels of omega-6 in the animal and also in humans eating the omega-6 rich animals.
  • omega 3 ratio is of up to 60:1.
  • omega 6 to omega-3 ratio is of 1:1, while our current dietary habits are closer to 10-20:1.
  • omega-6 fatty acids are proinflammatory, and that processing and preparation of these protein rich foods often is high and harsh, it is highly questionable if the functions of the amino acids and peptides, including their antioxidant properties, are reduced or impaired.
  • the present Applicant has previously invented a food supplement, i.e. a composition comprising omega-3 fatty acids in a stable oil-in water emulsion (Norwegian Patent No 322041). Different aspects of the composition are described in the applicants patents/patent applications. (Norwegian Patent No 322041 and 324262, and the Norwegian Patent Application NO 20073267).
  • this stable oil-in-water emulsion is an excellent carrier for important biologically active peptides and/or amino acids.
  • bioactive peptides and/or amino acids are thus formulated in a composition for oral s administration, which has previously been a challenge due to the instability of the peptides in GI tract and low bioavailability.
  • the present invention provides a new composition combining the health promoting effect of bioactive amino acids and peptides together with the health promoting effect of omega-3 polyunsaturated fatty acids in a combined formula, revealing an oral formulation with improved bioavailability.
  • composition according to the invention protects the bioactive amino acids and peptides throughout the GI tract, and is increases the bioavailability of the active ingredients.
  • the omega-3 fatty acids of the composition will promote the penetration of amino acids and peptides through e.g. the blood-brain barrier and cell membranes, thus conferring the beneficial effects of both the polyunsaturated fatty acids and the bioactive peptides and amino acids.
  • the present invention provides a new composition combining the health promoting effect of bioactive amino acids and peptides and the health promoting effect of omega-3 polyunsaturated fatty acids in a combined formula for oral administration.
  • High stability in the marine emulsion and composition enables low oxidation and keeps the vulnerable nutrients intact and potent, and makes it possible to provide tasty deliveries.
  • the ingredients of the composition are formulated and targeted toward specific conditions and diseases. For instance formulations for improving Alzheimer, autistic conditions, cancer conditions, diabetes, recovery and restitution, cardiovascular health, osteoporosis, asthma, depressions, muscle recovery and adaption to sports and endurance, are provided.
  • composition reveals surprising characteristics as to bioavailability of the peptides and/or amino acids. Compared to prior art where corresponding amounts of omega-3 and peptides or amino acids are consumed in different, separate formulas e.g. pills, capsules, powders etc, the composition according to the present invention shows improved delivery, improved uptake and improved health impact.
  • one object of the present invention is to provide a composition combining specific potent and biologically active peptides and/or amino acids in an oral formulation.
  • Another object of the present invention is to provide a composition combining specific potent and biologically active peptides and/or amino acids and omega -3 fatty acids in an oral formulation.
  • Another object of the present invention is to provide a composition combining specific potent and biologically active peptides and/or amino acids and omega-3 fatty acids in an oral formulation, wherein said composition enhances the bioavailability of the active ingredients.
  • Yet another object of the present invention is to provide a composition combining specific potent and biologically active peptides and/or amino acids and omega-3 fatty acids in an oral formulation, in order to restore cell balance.
  • Yet another object of the present invention is to provide a composition combining specific is potent and biologically active peptides and/or amino acids and omega-3 fatty acids in an oral formulation, in order to restore the neurological balance.
  • one aspect of the present invention relates to a composition
  • a composition comprising at least one bioactive amino acid or peptide or derivative thereof and marine oil in a stable oil-in-water emulsion.
  • bioactive peptides and/or amino acids of the invention include, but are not limited to, L-carnosine, or the precursors beta-alanine and histidine, glutahione or precursor cysteine or glutamine, food derived ACE inhibitory peptides, BCAA (branched chain amino acids) such as leucin, valin, isolecin, casein phospo peptides, collagen peptide, taurin and theanine.
  • BCAA branched chain amino acids
  • the content of the different bioactive peptides or amino acids may vary, but is preferably in an amount corresponding to the recommended daily dose.
  • the marine oil may be any oil rich in omega-3, e.g. fish oil, seal oil or krill oil.
  • the oil may be mixed with other polyunsaturated oils of vegetable origin such as algae oil or herbal oil e.g. evening primrose oil and rapeseed oil.
  • One preferred embodiment of the present invention provides a composition wherein the content of the marine oil is about 0.5%-15% by weight. Within this range the following ranges are preferred: about 1.5%-7% , about 1.5%-5% and most preferably about 1.5%-3% or about 0.5%-7% and most preferably about 0.5%-3%.
  • the marine oil may be selected from any marine oil preparation of appropriate quality. To be of appropriate quality the level of oxidation given as the totox-value (2 times the peroxide value (PV) added with the anisidine value (AV)) should be as low as possible and preferably below 10 and most preferably below 5. Said oils are clear oils with a very mild fishy odour and taste.
  • the daily requirement of marine oil are reach by consuming about 50-100 s ml of the composition according to the invention.
  • the recommended daily dose of omega-3 for adults are 650 mg given by ISSFAL—International Society for the Study of Fatty Acids.
  • the recommendation for children is about half the dosage of an adult, i.e. 350 mg.
  • any suitable emulsifier or combinations thereof may be used.
  • Milk solid, whey protein and pectin or any combination thereof are preferred emulsifiers.
  • the water phase of the oil-in water emulsion is preferably a water phase containing natural antioxidants e.g. fruit/vegetable juices, green tea, white tea and herbal tea.
  • the water phase may also contain proteins such as soy, oat proteins, whey proteins and/or milk proteins.
  • composition according to the invention may further comprise sweetener, flavouring is agents, antioxidants, minerals, vitamins and preservatives. As such the composition may be given any desirable taste.
  • the drink may be added prebiotics and/or probiotics. In another aspect of the present invention, the drink may be carbonated.
  • the composition may be in the form of any oral ingestible form.
  • the consistency of the composition may vary from a liquid low viscosity drink to a more viscous drink, e.g. a smoothie.
  • the consistency of the composition may be creamy like yoghurt.
  • the composition according to the invention is a drinkable composition.
  • a further aspect of the present invention relates to a process for the production of the composition.
  • the composition is prepared as described in the previous patents/patent applications mentioned.
  • Specific peptides or amino acids are added either in the water phase or directly to the emulsion after pasteurisation and/or homogenization.
  • bioactive amino acids and/or peptides and, if applicable, further water soluble additives are added to the water phase, together with a proportion of the emulsifier,
  • the emulsion obtained is optionally subjected to pasteurization and/or homogenization processes,
  • bioactive amino acids and/or peptides are added to the obtained emulsion,
  • the clean disposable container is a preferably sealed container, made of any suitable material.
  • the composition in the form of a drink may be an functional drink, a medical drink or a drug delivery (in a drink format).
  • the drink has a base containing natural antioxidants e.g. fruit or vegetable juice, green tea, but any drinkable liquid may be used, including milk, soya milk, oat milk, rice milk.
  • a further aspect of the present invention relates a composition for use as a therapeutic drink.
  • a drink according to the invention for the production of a medical preparation for the prophylaxis or treatment of diseases associated with elevated oxidative stress, such as cancer, inflammatory disorders, neurological disorders, cardiovascular disorders and respiratory disorders.
  • the specific formulation of the invention is believed to be of great importance, presenting the essential nutrients and specific health promoting agents (omega 3 fatty acids and peptides and/or amino acids) to the digestive system and to the cells in a format highly beneficial to the cells and the body.
  • essential nutrients and specific health promoting agents omega 3 fatty acids and peptides and/or amino acids
  • FIG. 1 shows the levels of carnosine and percent of newly synthesized carnosine in brain, heart and skeletal muscle.
  • Composition comprising fresh marine omega-3 emulsion, L-carnosine, selenium, zinc, iodine, and vitamin D.
  • Composition comprising fresh marine omega-3 emulsion, glutathione (reduced), selenium, B6 and B 12
  • Composition comprising fresh omega-3 emulsion, taurine and zinc glutonate
  • a tank is filled with purified and deionised water.
  • the active ingredients in the form of is peptides and/or amino acids or their derivatives or precursors are mixed in the water phase. Further, water soluble additives are added.
  • the oil is mixed with rosemary extract, Toco 50 (an antioxidant preparation favourable to the zo stabilization of the oil). It is important that the oil is protected against oxidation during processing. Thereafter, the emulsifier or emulsifier combination is added, mixed gently at room temperature to a homogenous mixture. At least the oil soluble additives, e.g. flavouring agents are added.
  • the oil phase may be mixed with the water phase after which the emulsifier is added and an emulsion is obtained.
  • the fruit concentrates are then added to the emulsion obtained and mixed thoroughly.
  • the emulsifier or emulsifier combination may be added partly to the water phase and partly to the oil phase.
  • the obtained emulsion may alternatively be subjected to a quick pasteurization (about 90° C. for 8 s), followed by homogenization and cooling to a temperature of 4-8° C.
  • the active ingredients in the form of peptides and/or amino acids or their derivatives or precursors are added to the obtained emulsion after the pasteurization and homogenization step through specialized systems as Flexdose (Tetra Pack solution), or added into a sterile tank through an ultra pure process.
  • the drink is filled on airtight aseptic containers, preferably single dose containers, e.g. Tetra Brick about 200 ml and stored at 6-8° C. until use.
  • airtight aseptic containers preferably single dose containers, e.g. Tetra Brick about 200 ml and stored at 6-8° C. until use.
  • Carbonated composition comprising fresh omega-3 emulsion, beta-alanine and vitamine D3. Batch size 300 kg.
  • One unit of 200 ml contains:
  • Beta-alanine 1 g
  • Vitamin D3 1.3 ⁇ g
  • composition were produced as follows:
  • the oil is mixed with Rosemary Extract, Toco 50 (antioxidants). It is important that this is done immediately to protect the oil from oxidation. About 50% of the pectin is added and carfully stirred into the oil (at room temperature) until fully mixed. Then the aromas, i.e. pomello and orange is mixed into the oil. The rest of the pectin (50%) is blended into the deionized water in the tank. The whey protein powder has been blended/dissolved in the water several hours before.
  • Purified and deionized water is filled into a tank. Whey protein powder has been dissolved in the water for several hours. The oil phase is introduced in the water phase
  • the oil phase is mixed to the water phase and then emulsified. Mixing time approx. 4 min
  • the fruit concentrates are blended into the emulsion and mixed thoroughly.
  • the least acid fruit concentrate is blended in first. Start with the pear concentrate and finish with the apple juice. Mixing time approx. 9 minutes. A rapid pasteurization—approx 90 degrees for 8 seconds.
  • the aim of this study was to investigate the uptake of 3-alanine supplemented to “Smartfish” and its conversion to carnosine in skeletal muscle, heart and brain.
  • Smartfish denotes a commercially available drink from the company Smartfish containing 1000 mg omega-3 and 1.3 ⁇ g vitamin D3 per 200 ml.
  • ⁇ -alanine is a naturally occurring beta amino acid, which differs from L- ⁇ -alanine with respect to the amino group's position on the carboxylate group. Together with histidine, alanine makes up the dipeptide carnosine. Conjugation of ⁇ -alanine and histidine, catalyzed by carnosine synthetase, takes place inside the cell and ⁇ -alanine is the rate limiting precursor of carnosine. Carnosine concentrations in skeletal muscle can reach high levels (4-8 mmol/kg wet weight) and has been studied quite extensively in relation to effect on exercise and muscle recovery. Studies of athletes supplemented with ⁇ -alanine have demonstrated improvements is in parameters of muscle function such as pH buffering and resistance to high intensity training.
  • ⁇ -alanine labeled with the stable isotopes C 13 and N 15 was purchased from Sigma-Aldrich and dissolved in Smartfish-juice (16.7 mg/ml).
  • Five female mice (C57BL/6J) age 10 weeks s were each supplemented with ⁇ 150 ⁇ l of the ⁇ -alanine fortified Smartfish two times each day for one week by oral gavage. This amount equals 200 mg/kg per day.
  • the following organs were dissected out; gastrocnemius, heart and brain and immediately frozen in liquid nitrogen, and stored at ⁇ 80° C.
  • Carnosine (Sigma-Aldrich) and 15N13C2-labeled carnosine (Sigma-Aldrich) concentrations in tissue were determined by HPLC-MS/MS operated in MRM mode.
  • Mouse tissues were homogenized in Methanolic HCL using a pellet grinder with cordless motor (Kontes). The homogenate was incubated for 30 min at 50° C. This procedure homogenized the tissue, precipitated proteins and methylated the carboxcylic acid group. is After centrifugation, the supernatant were injected directly into the LC-MS/MS system.
  • Calibrators were prepared by methylation of non labeled carnosine in methanolic HCl.
  • the HPLC column used was a Zorbax XDB 150 ⁇ 4.6 mm ID with 5 ⁇ m particles.
  • Heart tissue has the highest relative levels of isotope labeled carnosine as to total carnosine with almost 50% of the total amount of carnosine consisting of C 13 N 15 labeled carnosine.
  • the corresponding values in skeletal muscle and brain are 13 and 1.3% respectively.
  • Table 1 and 2 summarizes the data from all the individual samples in ⁇ g/g and mmol per kg wet weight, respectively.
  • results show that ⁇ -alanine is bioavailable and taken up by all the three target tissues, when supplemented as part of Smartfish.
  • results also show that tissues respond differently in terms of uptake and incorporation into carnosine.
  • the use of isotope labeled carnosine gave us more precise information about the relative uptake of ⁇ -alanine and some hints about the dynamics of the carnosine turnover. To our knowledge this approach for assessing carnosine levels has not been previously reported. However, the design of the study did not permit assessment of exactchanges in total carnosine levels as a result of ⁇ -alanine supplementation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
US13/377,869 2009-07-06 2010-07-06 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition Abandoned US20120148679A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20092564A NO333013B1 (no) 2009-07-06 2009-07-06 Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
NO20092564 2009-07-06
PCT/NO2010/000271 WO2011005113A1 (en) 2009-07-06 2010-07-06 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2010/000271 A-371-Of-International WO2011005113A1 (en) 2009-07-06 2010-07-06 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/208,716 Division US10105401B2 (en) 2009-07-06 2014-03-13 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Publications (1)

Publication Number Publication Date
US20120148679A1 true US20120148679A1 (en) 2012-06-14

Family

ID=43429376

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/377,869 Abandoned US20120148679A1 (en) 2009-07-06 2010-07-06 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition
US14/208,716 Active US10105401B2 (en) 2009-07-06 2014-03-13 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/208,716 Active US10105401B2 (en) 2009-07-06 2014-03-13 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition

Country Status (8)

Country Link
US (2) US20120148679A1 (no)
EP (2) EP2451439A4 (no)
CN (1) CN102711731B (no)
AU (1) AU2010269242B2 (no)
BR (1) BR112012000115B8 (no)
CA (1) CA2764792C (no)
NO (1) NO333013B1 (no)
WO (1) WO2011005113A1 (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014093987A (ja) * 2012-11-12 2014-05-22 Myp Co Ltd 鶏用飼料及び鶏の飼育方法
WO2015086789A1 (en) * 2013-12-13 2015-06-18 Nestec S.A. Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
EP2720701B1 (en) * 2011-06-15 2017-08-09 Stable Solutions Llc Therapeutic application of parenteral krill oil
US20150209306A1 (en) * 2012-08-07 2015-07-30 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
CN105283190A (zh) * 2013-06-13 2016-01-27 飞鱼有限公司 包含白藜芦醇或其衍生物的用于治疗、延缓和/或预防阿尔茨海默氏病的海洋油制剂
BR112015032029B1 (pt) * 2013-06-27 2021-04-06 Smartfish As Composição compreendendo óleo de peixe e suco para o tratamento de inflamação
NO20160913A1 (en) * 2016-05-27 2017-11-28 Smartfish As Use of a composition comprising marine oil and juice for improving muscle performance.
CN107494762A (zh) * 2017-08-24 2017-12-22 兰溪市捷喜食品加工技术有限公司 具有良好风味释放性的人造奶油及其制备方法
CN108208838A (zh) * 2018-03-09 2018-06-29 北京素维生物科技有限公司 一种掩味组合物及其用途
US11191289B2 (en) 2018-04-30 2021-12-07 Kraft Foods Group Brands Llc Spoonable smoothie and methods of production thereof
KR102555302B1 (ko) * 2020-05-28 2023-07-14 포항공과대학교 산학협력단 히비스커스, 로즈마리, 및 포도씨 추출물을 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료 조성물

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US20040015000A1 (en) * 2000-07-18 2004-01-22 Aanesen Berit Annie Process for stabilizing unsaturated oils
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20050209183A1 (en) * 2002-07-25 2005-09-22 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs
US7056938B1 (en) * 1999-06-25 2006-06-06 Academisch Ziekenhuis Bij De Univ. Method for scavenging radicals with urocanic acid, derivatives and analogues
WO2007064222A1 (en) * 2005-11-29 2007-06-07 Pharmalogica As Composition comprising fish oil and juice
US20080020102A1 (en) * 2004-07-13 2008-01-24 Rutgers, The State University Of New Jersey Omega Fatty Acid Fortified Food Products And Methods For Preparing Same
WO2009002184A1 (en) * 2007-06-25 2008-12-31 Pharmalogica As Carbonated beverage containing polyunsaturated fatty acids
US7504376B2 (en) * 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US8017170B2 (en) * 2002-08-29 2011-09-13 University Of Massachusetts Utilization of emulsion interface engineering to produce oxidatively stable lipid delivery systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381777D1 (de) * 1982-12-09 1990-09-06 Advanced Drug Tech Einfach absorbierbare fettsaeureemulsionen.
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
SE518823C2 (sv) 1994-07-12 2002-11-26 Karlshamns Lipidteknik Ab Olja-i-vatten-emulsioner
US6440464B1 (en) 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
JP2001078702A (ja) * 1999-07-12 2001-03-27 Nippon Suisan Kaisha Ltd まろやかさ、後味、うま味が増強された調味料
JP3121331B1 (ja) 1999-09-13 2000-12-25 オーケー食品工業株式会社 惣菜の味付方法
GB9925709D0 (en) * 1999-10-30 1999-12-29 Smithkline Beecham Plc Composition
NO313076B1 (no) 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
FR2820213B1 (fr) 2001-01-31 2004-10-22 Schlumberger Systems & Service Dispositif d'alimentation electrique pour une installation de tests de composants
GB0314624D0 (en) * 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
US8628690B2 (en) * 2004-02-23 2014-01-14 The Texas A&M University System Nanoemulsion compositions and methods of use thereof
NO322041B1 (no) 2004-10-22 2006-08-07 Pharmalogica As Naeringsmiddelsupplement inneholdende fiskeolje og melkefaststoff som emulgator og fremgangsmate for fremstilling.
NO323665B1 (no) 2005-06-27 2007-06-18 Pharmalogica As Drikk omfattende fiskeolje og probiotiske bakterier og fremgangsmate for fremstilling.
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US7504376B2 (en) * 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US7056938B1 (en) * 1999-06-25 2006-06-06 Academisch Ziekenhuis Bij De Univ. Method for scavenging radicals with urocanic acid, derivatives and analogues
US20040015000A1 (en) * 2000-07-18 2004-01-22 Aanesen Berit Annie Process for stabilizing unsaturated oils
US20050209183A1 (en) * 2002-07-25 2005-09-22 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs
US8017170B2 (en) * 2002-08-29 2011-09-13 University Of Massachusetts Utilization of emulsion interface engineering to produce oxidatively stable lipid delivery systems
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20080020102A1 (en) * 2004-07-13 2008-01-24 Rutgers, The State University Of New Jersey Omega Fatty Acid Fortified Food Products And Methods For Preparing Same
WO2007064222A1 (en) * 2005-11-29 2007-06-07 Pharmalogica As Composition comprising fish oil and juice
WO2009002184A1 (en) * 2007-06-25 2008-12-31 Pharmalogica As Carbonated beverage containing polyunsaturated fatty acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Kern et al., Effects of beta-alanine supplementation on performance and body composition in collegiate wrestlers and football players, Journal of the International Society of Sports Nutrition, 6(Suppl 1):P2, 2009 *
Life'09, Beta-alanine fights fatigue, Jan. 2009, Life Magazine *
Partos, New study investigates alternative emulsifiers to non-GM soya lecithin, Web page, July 28, 2005 *
Smith et al., Effects of beta-alanine supplementation and high-intensity interval training on endurance performance and body composition in men; a double-blind trial, Journal of the International Society of Sports Nutrition 2009, 6:5 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014093987A (ja) * 2012-11-12 2014-05-22 Myp Co Ltd 鶏用飼料及び鶏の飼育方法
WO2015086789A1 (en) * 2013-12-13 2015-06-18 Nestec S.A. Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions
CN105979796A (zh) * 2013-12-13 2016-09-28 雀巢产品技术援助有限公司 改性甜乳清及包含改性甜乳清的婴儿配方食品用于促进婴儿中枢神经系统和相关认知功能出生后发育的用途
US10517918B2 (en) 2013-12-13 2019-12-31 Societe Des Produits Nestle S.A. Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions

Also Published As

Publication number Publication date
WO2011005113A1 (en) 2011-01-13
AU2010269242A1 (en) 2012-01-19
CN102711731B (zh) 2015-02-18
CA2764792C (en) 2019-01-15
CN102711731A (zh) 2012-10-03
BR112012000115B1 (pt) 2020-10-27
EP3375436A1 (en) 2018-09-19
EP2451439A1 (en) 2012-05-16
NO333013B1 (no) 2013-02-18
NO20092564A1 (no) 2011-01-07
BR112012000115B8 (pt) 2021-05-25
AU2010269242B2 (en) 2014-05-22
US20140287054A1 (en) 2014-09-25
CA2764792A1 (en) 2011-01-13
US10105401B2 (en) 2018-10-23
EP2451439A4 (en) 2013-09-11
BR112012000115A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
US10105401B2 (en) Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition
KR102100091B1 (ko) 영양 조성물
JP2006503105A (ja) ロイシンに富んだ栄養的組成物
JPS6236645B2 (no)
JP2011157329A (ja) ミトコンドリア機能向上剤
WO2011096413A1 (ja) 運動機能改善剤
EP2134332A1 (en) Use of hydroxytyrosol as anti-aging agent
US20210259285A1 (en) Use of a composition comprising marine oil and juice for improving muscle performance
CN108697679B (zh) 含氨基酸的组合物
CN115279209A (zh) 辅酶q产生促进剂和辅酶q产生促进方法
JP5922862B2 (ja) ミトコンドリア機能向上剤
US20220211079A1 (en) Omega-3 Beverage
JP5922863B2 (ja) 運動機能改善剤
WO2019139032A1 (ja) 癌患者筋肉量減少抑制組成物
JP2002159279A (ja) 酸素有効利用能改善剤
JP2019108364A (ja) 栄養組成物
JP6734101B2 (ja) 心拍数回復促進組成物
JP6225199B2 (ja) 運動機能改善剤
WO2022250040A1 (ja) 鉄欠乏性貧血の改善または予防用組成物
US11058657B2 (en) Nutritional composition for use in therapy of cancer patients
NO333305B1 (no) Sammensetning omfattende bioaktiv aminosyre eller derivater derav og marin olje i en stabil olje-i-vann emulsjon, og fremgangsmate for fremstilling av nevntesammensetning samt forseglet beholder inneholdende sammensetningen
TW201825011A (zh) 蛋白質效率提升用之組成物

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMARTFISH AS, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATHISEN, JANNE SANDE;MATHISEN, HENRIK;REEL/FRAME:027767/0571

Effective date: 20120209

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION